Vaccine Contract Manufacturing Market Summary
The global Vaccine Contract Manufacturing market was valued at approximately USD 2,282.36 million in 2024 and is projected to reach nearly USD 3,905.96 million by 2032, growing at a CAGR of 6.9% during 2025–2032. The market is being driven by increasing global vaccine demand, expanding immunization programs, the emergence of infectious diseases, growing investments in novel vaccine platforms, and the need for flexible and scalable manufacturing capabilities.
Vaccine contract manufacturing enables pharmaceutical and biotechnology companies to outsource vaccine production to specialized contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). These organizations provide capabilities across formulation, bulk production, process development, filling, finishing, and other manufacturing activities, allowing vaccine developers to expand production without building extensive internal infrastructure.
The increasing complexity of vaccine technologies, including RNA, viral-vector, recombinant, and other advanced platforms, is further creating demand for specialized manufacturing partners. The emergence of diseases such as COVID-19, mpox, Nipah virus, and other infectious threats has also highlighted the importance of rapid, scalable, and geographically diversified vaccine manufacturing capacity.
Explore DelveInsight’s Full Coverage on the Vaccine Contract Manufacturing Market
Vaccine Contract Manufacturing Overview
Vaccine contract manufacturing refers to the outsourcing of vaccine production activities to specialized third-party manufacturers. Pharmaceutical companies, biotechnology companies, research organizations, and other developers can leverage the infrastructure, technical expertise, regulatory capabilities, and production capacity of CMOs and CDMOs to manufacture vaccines at commercial or clinical scales.
The model has become increasingly important as vaccine development requires sophisticated facilities, specialized expression systems, stringent quality controls, and extensive regulatory compliance. Contract manufacturers can support different stages of vaccine production while helping developers reduce the requirement for capital-intensive manufacturing infrastructure.
The vaccine contract manufacturing landscape encompasses multiple vaccine technologies, including inactivated vaccines, live attenuated vaccines, RNA vaccines, subunit vaccines, and toxoid-based vaccines. It also involves bacterial, baculovirus/insect, mammalian, and yeast expression systems, supporting a diverse range of vaccine manufacturing requirements.
Vaccine Contract Manufacturing Market Dynamics
The growing demand for vaccines represents one of the primary factors supporting market expansion. Routine immunization programs, booster campaigns, preventive healthcare initiatives, and the need to respond to emerging infectious diseases are increasing the requirement for reliable manufacturing capacity.
The emergence of new diseases has further emphasized the importance of flexible manufacturing infrastructure. Recent outbreaks and continued concerns surrounding diseases such as mpox, COVID-19, Nipah virus, and other emerging infections are encouraging governments and pharmaceutical companies to strengthen vaccine supply chains and production capabilities.
The expansion of biobanks is another factor supporting the market. Biobanks provide biological samples and associated resources that can facilitate vaccine research and development, potentially accelerating the transition from research to manufacturing.
At the same time, increasing investment in advanced vaccine platforms is creating additional opportunities. mRNA technologies and other innovative platforms require specialized production capabilities, encouraging developers to partner with organizations that already possess advanced manufacturing infrastructure.
However, stringent regulatory requirements remain a challenge. Vaccine manufacturers must comply with extensive quality, safety, validation, and regulatory standards that can vary across countries. In addition, certain vaccines require complex cold-chain storage and transportation, creating logistical and infrastructure challenges that can increase manufacturing and distribution costs.
Vaccine Contract Manufacturing Market Players
Key companies operating in the Vaccine Contract Manufacturing market include:
- Sanofi
- Biovac
- Emergent BioSolutions Inc.
- Lonza Group
- Catalent Inc.
- Boehringer Ingelheim BioXcellence
- Wockhardt
- WuXi Biologics
- Moderna, Inc.
- Syngene International
- Meridian Life Sciences
- Eurogentec
- IDT Biologika
- Serum Institute of India
- GlaxoSmithKline (GSK)
- Soligenix Inc.
- Curia
- Cobra Biologics
- BioReliance
- Recipharm
- Jubilant HollisterStier
- And Others
Vaccine Contract Manufacturing Market Segmentation
The Vaccine Contract Manufacturing market is segmented by vaccine type, expression system, end-user, and geography.
By vaccine type, the market includes inactivated vaccines, live attenuated vaccines, RNA vaccines, subunit vaccines, and toxoid-based vaccines. Inactivated vaccines are expected to maintain a significant position because of their established manufacturing processes, safety profile, and widespread use in immunization programs.
By expression system, the market is categorized into bacterial expression systems, baculovirus/insect expression systems, mammalian expression systems, and yeast expression systems.
By end-user, the market is segmented into pharmaceutical and biotechnology companies, research institutes and academic laboratories, and others.
Geographically, the market covers North America, Europe, Asia-Pacific, and the Rest of the World, with further analysis of major countries including the United States, Canada, Mexico, Germany, France, the United Kingdom, Italy, Spain, China, Japan, India, Australia, South Korea, and other regional markets.
Vaccine Contract Manufacturing Market Outlook
The Vaccine Contract Manufacturing market outlook remains positive through 2032, supported by increasing vaccine requirements and the growing preference for outsourcing specialized manufacturing activities. The market is expected to benefit from pharmaceutical companies seeking scalable production capacity while focusing internal resources on vaccine discovery, clinical development, commercialization, and distribution.
North America is expected to hold the largest share of the global vaccine contract manufacturing market in 2024. The region’s established healthcare infrastructure, high investment in biopharmaceutical research and development, stringent regulatory environment, and presence of sophisticated CMOs and CDMOs provide a strong foundation for market leadership.
The region also benefits from high vaccination coverage and continued investment in vaccine manufacturing infrastructure. Increasing demand for vaccines against infectious diseases and the development of next-generation vaccine technologies are expected to sustain the requirement for large-scale and technologically advanced manufacturing capabilities.
Recent Developments in Vaccine Contract Manufacturing
The vaccine manufacturing ecosystem has witnessed several strategic investments and partnerships designed to strengthen production capacity and regional supply security.
- In June 2024, Sanofi and Biovac announced a local manufacturing partnership to produce inactivated polio vaccines in Africa, supporting regional vaccine manufacturing and potentially serving more than 40 African countries.
- In August 2024, Africa CDC entered into a strategic agreement with Bavarian Nordic to increase mpox vaccine production in Africa.
- In July 2024, AstraZeneca announced an investment of USD 254 million at its Cambridge facility to expand vaccine manufacturing capabilities.
- In May 2024, BioNTech received USD 145 million from CEPI to expand mRNA vaccine production capacity.
- In September 2024, Moderna announced plans to establish an mRNA vaccine manufacturing facility in Quebec, Canada, reflecting continued investment in regional production capacity.
These investments and partnerships demonstrate the increasing strategic importance of distributed manufacturing capabilities, advanced vaccine technologies, and regional supply resilience.
Download the Vaccine Contract Manufacturing market report for in-depth insights on market size, competitive landscape, segmentation, and forecast.
Vaccine Contract Manufacturing Growth Opportunities
Government initiatives aimed at strengthening domestic and regional vaccine manufacturing represent an important opportunity for the market. The COVID-19 pandemic demonstrated the vulnerability of global vaccine supply chains and encouraged governments to increase local manufacturing capabilities.
The expansion of manufacturing capacity in emerging markets, particularly in Africa and Asia-Pacific, could create significant opportunities for CMOs and CDMOs. Regional production can reduce dependence on imports, improve vaccine availability, and support faster responses to outbreaks.
The development of mRNA vaccines and other advanced platforms also presents an attractive opportunity. Companies with specialized facilities, flexible production lines, and expertise in advanced biologics manufacturing could benefit from increasing outsourcing requirements.
Furthermore, partnerships between vaccine developers, governments, global health organizations, and contract manufacturers are expected to support capacity expansion and technology transfer, particularly in regions seeking greater vaccine self-sufficiency.
Vaccine Contract Manufacturing Drugs and Technology Uptake
This section evaluates the adoption of vaccine manufacturing technologies based on production scalability, platform flexibility, regulatory requirements, manufacturing complexity, cost considerations, and demand across therapeutic and preventive vaccine applications.
Inactivated vaccine manufacturing is expected to remain important because of established production processes and broad use in large-scale immunization programs. At the same time, RNA vaccine manufacturing is expected to attract increasing attention as developers invest in next-generation platforms capable of supporting rapid vaccine development.
Contract manufacturers that can offer end-to-end services, advanced expression systems, flexible manufacturing capacity, stringent quality controls, and global regulatory support are likely to be better positioned to capture future outsourcing opportunities.
Conclusion
The Vaccine Contract Manufacturing market is expected to expand from USD 2,282.36 million in 2024 to approximately USD 3,905.96 million by 2032, registering a CAGR of 6.9% during 2025–2032. Rising vaccine demand, expanding immunization programs, emerging infectious diseases, increased biopharmaceutical development, and investments in next-generation vaccine platforms are expected to remain key growth drivers.
While stringent regulatory requirements and complex cold-chain logistics present challenges, the increasing need for scalable and flexible manufacturing capacity is creating significant opportunities for CMOs and CDMOs. Strategic investments by companies such as AstraZeneca, BioNTech, Moderna, Sanofi, and other industry participants further demonstrate the importance of manufacturing capacity in strengthening global vaccine supply.
As pharmaceutical and biotechnology companies increasingly outsource production to specialized partners, vaccine contract manufacturing is expected to become an increasingly important component of the global vaccine ecosystem, supporting faster commercialization, supply-chain resilience, and broader access to vaccines.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
